Medifacts awarded a $1.9M contract to provide cardiac safety services

MEDIFACTS INTERNATIONAL, INC., one of the largest global providers of noninvasive cardiac diagnostic services, today announced the award of a $1.9 million contract with a Global pharmaceutical company to provide comprehensive cardiac safety and efficacy services for a large late stage clinical trial.

Demonstrating a unique ability to combine multiple technology platforms and innovative and efficient study design in one offering, Medifacts will provide consulting, equipment and an array of services for a cardiac safety study set across 180 sites worldwide.

Michael Woehler, Medifacts International’s President and Chief Executive Officer, said: "We are excited the industry continues to recognize the superior quality of Medifacts’ global services and entrust us with their key programs. Medifacts and our WebHeart^® platform continue to set the global standard in cardiac safety and efficacy data collection, management and submission. Medifacts International’s commitment to our sponsors’ rigorous expectations continues to pay dividends as we advance our position as one of the top 3 global cardiac safety businesses.”

www.medifacts.com